The safety and use of canarypox vectored vaccines.

S. A. Plotkin, M. Cadoz, B. Meignier, C. Méric, O. Leroy, J. L. Excler, J. Tartaglia, E. Paoletti, E. Gönczöl, G. Chappuis

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

ALVAC recombinants have been administered to humans and animals by parenteral and oral routes without giving signs of replication, systemic dissemination or severe reaction. In principle, it should be impossible for canarypox recombinants to disseminate in the environment as they would not be synthesised in mammalian cells as complete virus. Canarypox vectors have been safe for humans, in whom there has been no evidence of replication, but more work needs to be done to prove absence of replication. Recombinants are immunogenic by the intramuscular and subcutaneous routes. They are also immunogenic when given orally, but the dose required is still under study. Canarypox recombinants effectively prime the immune system for induction of antibodies and CD8 cell-mediated cytotoxicity by protein antigens. Antibody responses are not influenced by prior inoculation of canarypox, of subunit vaccine corresponding to the gene insert, or of vaccinia. Canarypox virus is attenuated for canaries, in which species it is already widely used. In principle, it is non-infectious for humans or other mammals. It may be infectious for other birds.

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalDevelopments in Biological Standardization
Volume84
Publication statusPublished - 1995

Fingerprint

Vaccines
Safety
Canarypox virus
Canaries
Vaccinia
Subunit Vaccines
Birds
Antibody Formation
Mammals
Immune System
Viruses
Antigens
Antibodies
Genes
Proteins

ASJC Scopus subject areas

  • Biotechnology

Cite this

Plotkin, S. A., Cadoz, M., Meignier, B., Méric, C., Leroy, O., Excler, J. L., ... Chappuis, G. (1995). The safety and use of canarypox vectored vaccines. Developments in Biological Standardization, 84, 165-170.

The safety and use of canarypox vectored vaccines. / Plotkin, S. A.; Cadoz, M.; Meignier, B.; Méric, C.; Leroy, O.; Excler, J. L.; Tartaglia, J.; Paoletti, E.; Gönczöl, E.; Chappuis, G.

In: Developments in Biological Standardization, Vol. 84, 1995, p. 165-170.

Research output: Contribution to journalArticle

Plotkin, SA, Cadoz, M, Meignier, B, Méric, C, Leroy, O, Excler, JL, Tartaglia, J, Paoletti, E, Gönczöl, E & Chappuis, G 1995, 'The safety and use of canarypox vectored vaccines.', Developments in Biological Standardization, vol. 84, pp. 165-170.
Plotkin SA, Cadoz M, Meignier B, Méric C, Leroy O, Excler JL et al. The safety and use of canarypox vectored vaccines. Developments in Biological Standardization. 1995;84:165-170.
Plotkin, S. A. ; Cadoz, M. ; Meignier, B. ; Méric, C. ; Leroy, O. ; Excler, J. L. ; Tartaglia, J. ; Paoletti, E. ; Gönczöl, E. ; Chappuis, G. / The safety and use of canarypox vectored vaccines. In: Developments in Biological Standardization. 1995 ; Vol. 84. pp. 165-170.
@article{729d97b04c714cdba8cf79b2b9df8f19,
title = "The safety and use of canarypox vectored vaccines.",
abstract = "ALVAC recombinants have been administered to humans and animals by parenteral and oral routes without giving signs of replication, systemic dissemination or severe reaction. In principle, it should be impossible for canarypox recombinants to disseminate in the environment as they would not be synthesised in mammalian cells as complete virus. Canarypox vectors have been safe for humans, in whom there has been no evidence of replication, but more work needs to be done to prove absence of replication. Recombinants are immunogenic by the intramuscular and subcutaneous routes. They are also immunogenic when given orally, but the dose required is still under study. Canarypox recombinants effectively prime the immune system for induction of antibodies and CD8 cell-mediated cytotoxicity by protein antigens. Antibody responses are not influenced by prior inoculation of canarypox, of subunit vaccine corresponding to the gene insert, or of vaccinia. Canarypox virus is attenuated for canaries, in which species it is already widely used. In principle, it is non-infectious for humans or other mammals. It may be infectious for other birds.",
author = "Plotkin, {S. A.} and M. Cadoz and B. Meignier and C. M{\'e}ric and O. Leroy and Excler, {J. L.} and J. Tartaglia and E. Paoletti and E. G{\"o}ncz{\"o}l and G. Chappuis",
year = "1995",
language = "English",
volume = "84",
pages = "165--170",
journal = "Developments in Biological Standardization",
issn = "0301-5149",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - The safety and use of canarypox vectored vaccines.

AU - Plotkin, S. A.

AU - Cadoz, M.

AU - Meignier, B.

AU - Méric, C.

AU - Leroy, O.

AU - Excler, J. L.

AU - Tartaglia, J.

AU - Paoletti, E.

AU - Gönczöl, E.

AU - Chappuis, G.

PY - 1995

Y1 - 1995

N2 - ALVAC recombinants have been administered to humans and animals by parenteral and oral routes without giving signs of replication, systemic dissemination or severe reaction. In principle, it should be impossible for canarypox recombinants to disseminate in the environment as they would not be synthesised in mammalian cells as complete virus. Canarypox vectors have been safe for humans, in whom there has been no evidence of replication, but more work needs to be done to prove absence of replication. Recombinants are immunogenic by the intramuscular and subcutaneous routes. They are also immunogenic when given orally, but the dose required is still under study. Canarypox recombinants effectively prime the immune system for induction of antibodies and CD8 cell-mediated cytotoxicity by protein antigens. Antibody responses are not influenced by prior inoculation of canarypox, of subunit vaccine corresponding to the gene insert, or of vaccinia. Canarypox virus is attenuated for canaries, in which species it is already widely used. In principle, it is non-infectious for humans or other mammals. It may be infectious for other birds.

AB - ALVAC recombinants have been administered to humans and animals by parenteral and oral routes without giving signs of replication, systemic dissemination or severe reaction. In principle, it should be impossible for canarypox recombinants to disseminate in the environment as they would not be synthesised in mammalian cells as complete virus. Canarypox vectors have been safe for humans, in whom there has been no evidence of replication, but more work needs to be done to prove absence of replication. Recombinants are immunogenic by the intramuscular and subcutaneous routes. They are also immunogenic when given orally, but the dose required is still under study. Canarypox recombinants effectively prime the immune system for induction of antibodies and CD8 cell-mediated cytotoxicity by protein antigens. Antibody responses are not influenced by prior inoculation of canarypox, of subunit vaccine corresponding to the gene insert, or of vaccinia. Canarypox virus is attenuated for canaries, in which species it is already widely used. In principle, it is non-infectious for humans or other mammals. It may be infectious for other birds.

UR - http://www.scopus.com/inward/record.url?scp=0029197894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029197894&partnerID=8YFLogxK

M3 - Article

C2 - 7796950

AN - SCOPUS:0029197894

VL - 84

SP - 165

EP - 170

JO - Developments in Biological Standardization

JF - Developments in Biological Standardization

SN - 0301-5149

ER -